After the mapping of the human DNA by the Human Genome Project, MGRC saw the need to fill what they believed was going to be a huge market in analytics. Even the government has high hopes in this area with a target of 15% contribution to GDP coming from the Bioeconomy. 40 patents and a few loss-bleeding years later, MGRC is beginning to see signs of profitability. The need to achieve greater investor understanding of the field of genetics is probably manifested in its poor share price performance.

<p>After the mapping of the human DNA by the Human Genome Project, MGRC saw the need to fill what they believed was going to be a huge market in analytics. Even the government has high hopes in this area with a target of 15% contribution to GDP coming from the Bioeconomy. 40 patents and a few loss-bleeding years later, MGRC is beginning to see signs of profitability. The need to achieve greater investor understanding of the field of genetics is probably manifested in its poor share price performance.</p>

Instagram

Sharper and stronger than a double espresso. The Morning Run stretches your mind and braces you for the business day. It's your fast track into work where you can hit the ground running. From 6am to 10am weekdays, the Morning Run brings you the biggest stories and must-listen-to interviews. Stay enlightened, make educated business and investment decisions.

Advertisement